AACE Obesity Pharmacotherapy: BMI 27+ With Comorbidity Rule
AACE, ADA, and Endocrine Society allow obesity drugs at BMI ≥30, or BMI ≥27 with a comorbidity. See how guidelines compare on thresholds and treatment eligibility.
Obesity (Condition)
22 source-based articles maintained by the HealthRX.com Editorial Team.
22articles
5topic areas covered
Jul 10, 2025latest review
Obesity (Condition) library
Showing 22 of 22 clinical reviews.
Comorbidities of Obesity: Diabetes, Heart Disease, Sleep Apnea
Obesity (BMI ≥30) raises risk for 200+ conditions, most notably type 2 diabetes, heart disease, sleep apnea, MASLD, and osteoarthritis. See how they overlap.
Exercise Prescription for Obesity (BMI ≥30): Evidence-Based Protocols and Guidelines
A guide to exercise prescription for adults with obesity (BMI ≥30), covering AHA, ACSM, and Endocrine Society recommendations with specific protocols, doses, and trial data.
NIH Obesity Guidelines: 500-750 kcal/Day Deficit Explained
NIH first-line obesity treatment: a 500-750 kcal/day deficit plus 150-300 min/week exercise, yielding 5-10% weight loss in 6 months to cut cardiometabolic risk.
Obesity (BMI ≥30) Caregiver and Family Resources
Evidence-based guide to caregiver support, family-based interventions, and practical resources for managing obesity (BMI ≥30), including behavioral strategies, medication awareness, and clinical guidelines from ADA, AACE, and the Endocrine Society.
Obesity (BMI ≥30) Commonly Missed Diagnoses: What Doctors Overlook and Why It Matters
Obesity is frequently misdiagnosed or its underlying drivers missed entirely. This clinical guide covers the secondary causes, comorbidities, and diagnostic blind spots every patient and clinician needs to know.
Obesity (BMI ≥30) Emergency Symptoms Requiring 911
Learn which obesity-related emergency symptoms require calling 911 immediately, including hypertensive crisis, pulmonary embolism, acute MI, and severe hypoglycemia. Written by the HealthRX.com medical team and reviewed by board-certified physicians.
Obesity (BMI ≥30) Exact Monitoring Schedule
A guideline-backed monitoring schedule for adults with obesity (BMI ≥30), covering lab work, vitals, metabolic panels, and follow-up intervals during pharmacotherapy and lifestyle intervention.
Obesity (BMI ≥30) Global Prevalence and Trends
A data-driven overview of how obesity rates have changed worldwide, which populations carry the highest burden, and what current epidemiology means for clinical practice.
Obesity (BMI ≥30) Partner and Family Role: A Complete Clinical Guide
How partners and family members can support obesity treatment. Evidence-based strategies covering shared lifestyle change, emotional support, medication adherence, and what the guidelines say.
Obesity (BMI ≥30) Racial and Ethnic Disparities
A clinical deep-dive into why Black, Hispanic, Native American, and Pacific Islander adults carry a disproportionate burden of obesity, what drives those gaps, and how current guidelines address them.
Obesity (BMI ≥30) Socioeconomic Impact: Costs, Productivity, and Disparities
A deep dive into the socioeconomic burden of obesity, covering direct medical costs, lost productivity, wage penalties, health disparities, and what current evidence says about reducing that burden.
Obesity (BMI ≥30): Emerging Research and Trials to Watch
A clinical review of the most promising obesity trials, next-generation GLP-1 receptor agonists, combination therapies, and gene-based approaches reshaping how we treat BMI ≥30.
Obesity (BMI ≥30): Finding the Right Clinical Trial
A guide to identifying, evaluating, and enrolling in obesity clinical trials. Covers eligibility criteria, major active trials, GLP-1 and combination therapies, and step-by-step enrollment guidance for adults with BMI ≥30.
Obesity (BMI ≥30): History of Treatment Over Decades
A comprehensive clinical history of obesity treatment from early dietary regimens to modern GLP-1 receptor agonists, with primary-source citations and guideline references for patients and clinicians.
Obesity (BMI ≥30): Pediatric vs Adult Differences
A comprehensive clinical comparison of pediatric and adult obesity, covering diagnostic criteria, comorbidities, treatment guidelines, and pharmacologic options with primary-source citations.
Obesity (BMI ≥30): When to Seek a Second Opinion
A guide to recognizing when your obesity treatment plan needs a fresh set of eyes, covering BMI thresholds, FDA-approved medications, surgery criteria, and second-opinion triggers backed by major society guidelines.
Obesity Genetics and Family History: What Your DNA Means for Weight and Treatment
How genetics and family history influence obesity risk, BMI heritability, known gene variants like MC4R and FTO, and what this means for GLP-1 and other treatments.
Obesity Treatment Algorithm: A Line-by-Line Guide to Evidence-Based Therapy
Step-by-step obesity treatment algorithm organized by line of therapy, from lifestyle intervention through pharmacotherapy and metabolic surgery, based on ADA, AACE, and Endocrine Society guidelines.
Obesity Treatment in Special Populations: Evidence-Based Approaches for Complex Patients
How obesity management differs for older adults, adolescents, pregnant patients, and those with CKD, diabetes, or psychiatric conditions. Guideline-backed strategies with trial data.
Psychological Monitoring for Obesity Medications
Obesity raises depression risk 55%; depression raises obesity risk 58%. Learn what to monitor and how to treat both conditions together.
Stopping Obesity Treatment Safely: What to Do When You Discontinue Weight-Loss Medication
A guide for adults with BMI ≥30 on how to stop FDA-approved obesity medications safely, minimize weight regain, and protect long-term metabolic health.